Early clinical and CT features of COVID-19 and community-acquired pneumonia from a fever observation ward in Ningbo, China.
- Author:
Guoqing QIAN
1
;
Yuanwei LIN
2
;
Xueqin CHEN
3
;
Ada Hoi Yan MA
4
;
Xuehui ZHANG
1
;
Guoxiang LI
1
;
Xinzhong RUAN
5
;
Liemin RUAN
6
Author Information
- Publication Type:Journal Article
- Keywords: COVID-19; SARS-CoV-2; clinical features; high-resolution CT; pneumonia
- MeSH: COVID-19/diagnostic imaging*; China; Community-Acquired Infections/diagnostic imaging*; Diarrhea/pathology*; Fever; Humans; Lung/diagnostic imaging*; Retrospective Studies; SARS-CoV-2; Tomography, X-Ray Computed/methods*
- From:Singapore medical journal 2022;63(4):219-224
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTION:We aimed to compare the early clinical manifestations, laboratory results and chest computed tomography (CT) images of COVID-19 patients with those of other community-acquired pneumonia (CAP) patients to differentiate CAP from COVID-19 before reverse transcription-polymerase chain reaction results are obtained.
METHODS:The clinical and laboratory data and chest CT images of 51 patients were assessed in a fever observation ward for evidence of COVID-19 between January and February 2020.
RESULTS:24 patients had laboratory-confirmed COVID-19, whereas 27 individuals had negative results. No statistical difference in clinical features was found between COVID-19 and CAP patients, except for diarrhoea. There was a significant difference in lymphocyte and eosinophil counts between COVID-19 and CAP patients. In total, 22 (91.67%) COVID-19 patients had bilateral involvement and multiple lesions according to their lung CT images; the left lower lobe (87.50%) and right lower lobe (95.83%) were affected most often, and all lesions were located in the peripheral zones of the lung. The most common CT feature of COVID-19 was ground-glass opacity, found in 95.83% of patients, compared to 66.67% of CAP patients.
CONCLUSION:Diarrhoea, lymphocyte counts, eosinophil counts and CT findings (e.g. ground-glass opacity) could help to distinguish COVID-19 from CAP at an early stage of infection, based on findings from our fever observation ward.